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Study design: Retrospective cohort study of 1430 patients undergoing lumbar spinal fusion from 2002 - 2009.
Objective: The goal of this study was to compare and evaluate the number of complications requiring reoperation
in elderly versus younger patients.
Summary of background data: rhBMP-2 has been utilized off label for instrumented lumbar posterolateral fusions
for many years. Many series have demonstrated predictable healing rates and reoperations. Varying complication
rates in elderly patients have been reported.
Materials and methods: All patients undergoing instrumented lumbar posterolateral fusion of ≤ 3 levels
consenting to utilization of rhBMP-2 were retrospectively evaluated. Patient demographics, body mass index,
comorbidities, number of levels, associated interbody fusion, and types of bone void filler were analyzed. The age
of patients were divided into less than 65 and greater than or equal to 65 years. Complications related to the
performed procedure were recorded.
Results: After exclusions, 482 consecutive patients were evaluated with 42.1% males and 57.9% females. Average
age was 62 years with 250 (51.9%) < 65 and 232 (48.1%) ≥ 65 years. Patients ≥ 65 years of age stayed longer
(5.0 days) in the hospital than younger patients (4.5 days) (p=0.005).
Complications requiring reoperation were: acute seroma formation requiring decompression 15/482, 3.1%, bone
overgrowth 4/482, 0.8%, infection requiring debridement 11/482, 2.3%, and revision fusion for symptomatic
nonunion 18/482, 3.7%. No significant differences in complications were diagnosed between the two age groups.
Statistical differences were noted between the age groups for medical comorbidities and surgical procedures.
Patients older than 65 years underwent longer fusions (2.1 versus 1.7 levels, p=0.001).
Discussion: Despite being older and having more comorbidities, elderly patients have similar complication and
reoperation rates compared to younger healthier patients undergoing instrumented lumbar decompression fusions
with rhBMP-2.Introduction
In the United States, improvements in health have
resulted in increased life expectancy and contributed to
the growth of the older population over the past century.
As in most western countries, U.S. demographics show a
graying trend over the last 30 years. In 1980, 11.31% of
the U.S. population were 65 years or older [1]. In 2010,* Correspondence: martinfhoffmann@gmx.net
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reproduction in any medium, provided the or12.97% of the US population were 65 years or older with
an estimated increase to 20% in the following 30 years
[1]. Today’s elderly are better educated and make higher
demands for mobility and quality of life [2]. Therefore,
the number of elderly patients presenting with degenera-
tive disease of the lumbar spine qualifying and requiring
surgery is expected to increase. In addition, elderly
patients frequently have lumbar stenosis treated with ex-
tensive decompressive laminectomy and subsequent
arthrodesis [3]. Instrumented posterolateral fusion is the
most common type of fusion performed in the lumbarral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for spinal arthrodesis is currently considered the “gold
standard” [4]. Advanced patient age, medical comor-
bidities, and declining bone quality of the vertebra and
iliac crest are important issues to consider when
selecting the graft treatment for lumbar spinal fusion
in older patients [5].
Degenerative lumbar spine diseases usually occur at
multiple levels and require a greater amount of bone
graft material [6]. Bone quality and bone availability are
reduced in elderly patients. Potential alternatives and
enhancements to autologous bone graft have gained at-
tention. A wide array of bone graft materials is used to
obtain solid fusion. The discovery of osteoinduction
through demineralized bone protein extracts and later
identification of bone morphogenetic proteins (BMPs)
[7,8] offers the potential to obtain fusion without iliac
crest bone graft harvesting or enhances the potential of
limited autologous bone grafts.
Recombinant human BMP-2 (rhBMP-2) is a growth
factor that belongs to the transforming growth factor-β
(TGF–β) superfamily. rhBMP-2 (INFUSE, Medtronic,
Memphis, TN) is commercially available for clinical use.
Clinical use of rhBMP-2 was approved by the U.S. Food
and Drug Administration (FDA) in 2002 for anterior
lumbar spine fusions from lumbar level four (L4) to sa-
cral one (S1) [9] and for the repair of symptomatic, pos-
terolateral lumbar spine pseudarthrosis [10]. Despite this
fact, off-label use of rhBMP-2 in combination with iliac
crest autograft and/or bone void fillers for posterolateral
intertransverse process fusion has become immensely
popular because of the need for larger bone graft
amounts required for this procedure especially in
patients with poor and limited bone quality. The use of
rhBMP-2 in posterolateral lumbar fusions is intended to
enhance fusion mass and reduce donor side morbidity
related to bone graft harvest [11] as described by Boden
[12]. Singh [13] showed enhanced fusion rates for iliac
crest bone graft in combination with rhBMP-2 compared
to iliac crest bone graft alone. Following these promising
results, rhBMP-2 utilization nationwide has increased to
28.1% of all fusion procedures [14].
Increasing age has been found as a risk factor for the
development of postoperative complications in posterior
lumbar decompression and arthrodesis [15]. Therefore,
BMP supplementation might be the solution to achieve
reliable fusion rates in elderly patients. In contradiction,
a recent report noted reduced fusion rates with rhBMP-
2 among adults over 65 years of age, which was attribu-
ted to weakened osteoinductive capacity in elderly
patients [6]. In addition, multiple complications attribu-
ted to BMPs have been observed [16,17]. According to
our knowledge, no correlation of these BMP specific
complications to age has been published. We assumethat there is a higher complication rate in older patients
and in patients with comorbidities. BMP related compli-
cations are uncommon and therefore a large study popu-
lation is necessary to determine complication rates.
The actual data is still lacking to determine an accept-
able safety profile for rhBMP-2 in posterolateral fusions
for older patients. The purpose of this retrospective co-
hort was to determine whether there was a difference in
the number of complications requiring reoperation in
elderly versus younger patients.
Materials and methods
This study was an Institutional Review Board approved
retrospective cohort exploratory review of patients under-
going instrumented lumbar posterolateral fusion utilizing
of rhBMP-2 (INFUSE) at a single private practice associated
with a tertiary referral spine center. It was approved by the
Spectrum Health Institutional Review Board, Grand Rapids,
Michigan. The IRB study # was 2007-123. Five fellowship
trained orthopaedic surgeons performed all operative pro-
cedures. Consecutive patients were identified by Current
Procedural Treatment (CPT) codes for fusion (22612,
22614), instrumentation (22840, 22842, and 22843) with
corresponding rhBMP insertion that had initial treatment
from March 2002 through June 2009, 7 years. Inclusion cri-
teria were: instrumented lumbar posterolateral fusion of
one to three levels with rhBMP-2 implant and age equal to
or older than eighteen years. Exclusion criteria were: thor-
acic fusions, additional anterior, posterior, or transforaminal
lumbar interbody fusion (ALIF, PLIF, TLIF), BMP products
other than rhBMP-2, follow up less than 6 months, and in-
sufficient medical record or radiographic data.
Of a total of 2406 lumbar fusions performed during the
study period, 598 patients underwent isolated instrumented
lumbar posterolateral fusion of ≤ 3 levels with the addition
of rhBMP-2. One hundred and sixteen (116) patients were
excluded because of death during hospitalized or post-
operative period (2), utilization of additional bone stimula-
tor (9), and inadequate follow up data (105). One death
during hospitalization occurred as a result of pulmonary
embolism and one death occurred four weeks after dis-
charge not related to the surgical procedure. 482 patients
were identified with a mean age of 62 years (range 18–89).
There were 203 (42.1%) males and 279 (57.9%) females.
Average body mass index (BMI) was 31.4 (18.4-63.9) kg/
m2.
In all patients, a trail of non-operative treatment includ-
ing non-steroidal anti-inflammatory drugs (NSAID), phys-
ical therapy, and/or spinal injections was ineffective. 395
patients had preoperative back pain. 325 patients had pre-
operative radicular leg pain. All patients had neurogenic
claudication. Surgery indications are listed in Table 1.
Diagnosis, spinal pathology, and surgeon’s best know-
ledge determined treatment. Therefore in total, 899




Back pain 395 82.0%
Radicular leg pain 325 67.4%





Failed previous fusion 18 3.7%
Table 2 Risk factor differences in age groups
Contributing factors Group 1 Group 2 Significance
(18-64 years) (≥65 years)
N=250 N=232
Gender χ²=0.292
male 111 (44.4%) 92 (39.7%)
female 139 (55.6%) 140 (60.3%)
BMI(kg/m²) 32.2a (18.4-63.9) 30.5 (18.5-57.2) p=0.006
Diabetes 35 (14.0%) 49 (21.1%) χ²=0.109
Cardiovascular
disease
114 (45.6%) 147 (63.4%) χ²<0.001
Respiratory disease 58 (23.2%) 40 (17.2%) χ²=0.104
Current Tobacco Use 51 (20.4%) 6 (2.6%) χ²<0.001
Allergies 121 (52.6%) 97 (46.0%) χ²=0.234
Steroid medication 53 (21.2%) 68 (29.3%) χ²=0.081
Preoperative NSAID 83 (37.7%) 107 (46.1%) χ²=0.010
Previous BMP
exposure
10 (4.0%) 8 (3.4%) χ²=0.740
BMI=Body Mass Index, BMP=Bone morphogenetic protein, NSAID= non-
steroidal anti-inflammatory drugs.
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31.7%), 2 (241, 50.0%), and 3 (88, 18.3%). Bone graft and
bone graft extenders were used at the surgeons’ discre-
tion. All patients underwent local autografting utilizing
decompressed posterior elements.
All patients were consented to lumbar decompression
and arthrodesis utilizing rhBMP with education and in-
formation of the off label utilization of rhBMP-2. All
patients received antibiotics (cefazolin) 30 minutes pre-
and 24 hours post-operatively. Some patients had pre-
operative and intraoperative steroids. Steroids were uti-
lized based upon patient symptoms, surgeon discretion,
and anesthesiologist experience. The posterolateral arth-
rodesis was prepared with decortication of the posterior
aspect of the transverse processes with a high-speed
burr. The posterior elements were denuded of soft tissue
or cartilaginous attachments, ground into small frag-
ments, and placed onto the transverse processes. The
rhBMP-2 was prepared according to manufacturer speci-
fications (Medtronic, Memphis, TN). The rhBMP-2
attached to the bovine collagen sponge was wrapped
around a bone void filler (BVF) such as Mastergraft
(Medtronic, Memphis, TN) or allograft bone (Musculo-
skeletal Transplant Foundation, MTF, West Chester, PA)
and placed onto the transverse processes and posterior
elements. The sponge required proximity and contact
with all transverse processes of the levels undergoing
arthrodesis. The surgeon determined the amount or
number of INFUSE kits utilized per surgery. The mean
total BMP-2 dose implanted was 12.4 mg per patient
(range 12.0-24.0). The mean dosage per level was 7.7 mg
(range 4.0-24.0). Once the procedure was completed, the
fascia was closed over a hemovac drain. The surgeon
determined the timing of drain removal.
Patient follow-up was performed at regular intervals of
two weeks, six weeks, twelve weeks, six months, one
year, and later if required or indicated. The mean follow
up period was 15.8 months (range 6–70 months). Clin-
ical examination, pain scales, and radiographic imaging
were performed at these intervals. Lumbar radiographsconsisted of anterior-posterior (AP) and lateral (Lat)
views. Flexion/extension radiographs or CT imaging was
performed to confirm arthrodesis, screw loosening, in-
stability, nonunion, ectopic bone formation, and/or cor-
tical erosion. MRI with gadolinium of the lumbar spine
was obtained if neural symptoms or pain indicated.
Complications related to the performed procedure were
recorded. Additional or revision surgeries were performed
when indicated.
Patients were grouped by age into Group 1: 18–64 years,
Group 2: ≥ 65 years. Comorbidities and potential contrib-
uting factors were recorded (Table 2). Descriptive statistics
were completed. Chi square and t-tests were used to com-
pare age groups less than 65 and those greater than or
equal to 65 for demographic data, complications contrib-
uting factors, and rhBMP-2 used. Data was analyzed using
PASW/SPSSW 18 (IBM, New York, NY).
Results
Mean length of hospital stay (LOS) was 4.7 days (range
2–21 days) for all age groups combined. Patients ≥ 65
years of age stayed longer (mean 5.0 days, range 2–21)
in the hospital than younger patients (mean 4.5 days,
range 2–12) (t=0.757, p=0.005). LOS was not affected by
the outlier of 21 days. In the <65 years group, 57% of the
patients had a LOS of 3 and 4 days. In the ≥ 65 years
group, 55% of the patients stayed in hospital for 4 and 5
days. No significant difference in length of stay between
patients with (4.75 ± 1.9 days) or without additional
iliac crest bone grafting (4.42 ± 1.8 days) was noted
(t = 0.966, p=0.335).
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gery due to surgical complications, with more than one
complication occurring in some patients. Eleven patients
had an intraoperatively diagnosed and repaired dural
tear (2.3%). Complications requiring reoperation were:
18 of 482 (3.7%) patients with a symptomatic nonunion,
15 of 482 (3.1%) patients with a painful perioperative
seroma formation required decompression with 5 posi-
tive intraoperative cultures (2 staphylococcus species, 1
methicillin resistant staphylococcus aureus, 2 propioni-
bacterium species), 15 of 482 (3.1%) patients with excess
bone reformation of which four required operative de-
compression (0.8%), 11 of 482 (2.3%) patients with infec-
tion, and one patient (0.2%) with malpositioned implant.
Mean age was 62 years (range 18–89) with an almost
even distribution between less than 65 years (250,
51.9%) and greater than or equal to 65 years (232,
48.1%). Gender distribution was similar between the two
groups with more female patients in the older age group
(60.3% versus 55.6%; χ2=0.292). Younger patients had a
greater body mass index (BMI) (32.2 kg/m2 versus 30.5
kg/m2; t=2.769, p=0.006). No difference in allergy pre-
disposition (χ2=0.234) was noted. Tobacco use was sig-
nificantly reduced in older patients (χ2<0.001). No
differences in preoperative steroid medication (χ2=0.081)
was found, but older patients were given non-steroidal
anti-inflammatory drugs at a higher rate of time (χ2=0.010).
Regarding comorbidities, a greater prevalence of cardiovas-
cular diseases (χ2=0.001) in older patients existed, while no
significant difference in respiratory diseases (χ2=0.104) or
diabetes (χ2=0.109) was demonstrated. No significant differ-
ence in previous BMP exposure (4.0% vs. 3.4%, χ2=0.740)
was elucidated.
Surgical treatment differed in both age groups. Patients
older than 65 years underwent longer fusions (2.1 levels
versus 1.7 levels, respectively, χ2<0.001), but no difference
in total rhBMP-2 dose (12.5 mg versus 12.3 mg respect-
ively; t=−0.934, p=0.351) or fusions utilizing more than
one large kit (12 mg) rhBMP-2 (4.3% versus 2.8% respect-
ively, χ2=0.369) was found. Elderly patients received lesser
rhBMP-2 doses per level (7.0 mg versus 8.4 mg respect-
ively; t=5.145, p<0.001).
Intraoperative diagnosed and repaired dural tears were
more common in elderly patients (2.6% and 2.0% re-
spectively; χ2<0.001). Revision surgery for clinically rele-
vant nonunion was necessary in 3.6% of less than 65
year old patients compared to 3.9% in greater than or
equal to 65 year old patients (χ2=0.872). A tendency to
greater seroma formation was found in younger patients
(4.4% versus 1.7% respectively, χ2=0.091). No significant
difference in infection rate was diagnosed between the
two age groups (χ2=0.857).
Comparing comorbidities as confounding factors for
complications, no association between diabetes mellitusand infection (χ2=0.810), seroma formation (χ2=0.052),
or nonunion (χ2=0.602) was found. Patients with existing
respiratory disease did not show higher rates of infec-
tion, seroma formation, or nonunion (χ2=0.090, 0.974,
and χ2=0.694 respectively). Patients with cardiovascular
disease had an increase in seroma formation (χ2=0.041)
but no differences for infection (χ2=0.062) or nonunion
rate (χ2=0.0791).
Discussion
Because of demographic changes and higher demands
for mobility and life style, the number of elderly patients
who seek help by orthopedic surgeons for lumbar path-
ology is increasing. In contrast to younger patients, de-
generative lumbar pathology with stenosis is the leading
cause for surgical intervention in the elderly [1]. Lumbar
decompression and fusion can produce improvements in
pain, ambulation, and activities of daily living [18] and
therefore provides an independent lifestyle paramount to
elderly patients. To achieve a solid fusion, stable instru-
mentation and a reasonable amount of osteoinductive
material is required. The most commonly used fusion
material is autologous iliac crest bone graft. Due to
multilevel fusions requiring extensive osteoinductive ma-
terial and poor bone quality void of osteoinductive ma-
terial in elderly patients, a large amount of iliac crest
bone graft is needed. Extensive graft harvest clearly
lengthens the surgical procedure, increases blood loss
[19], multiplies the chances of bone harvest related com-
plications, and frequently is inadequate or impossible.
To reduce the necessary amount of iliac crest autograft
and enhance fusion, bone void fillers in combination
with rhBMP-2 became a common supplement. Despite
its off-label use, 30.0% of BMP use is in primary TLIF/
PLIF procedures and 20.4% of BMP is used in primary
posterolateral spinal fusions [20]. Hence, the use of BMP
for lumbar spinal fusions can be considered as an op-
tional “standard of care” before the FDA has granted ap-
proval [20].
The initial cost of rhBMP-2 remains an important
concern. Possible cost reduction was attributed to fewer
complications and decreased length of hospital stay [21].
Previous studies showed an average hospital stay for
patients with lumbar spine fusion of 4 to 6 days
[14,17,21]. In our study, average length of stay for all
patients was 4.7 days. This is consistent with previous
studies [14]. Even though not fully elucidate, rhBMP-2
in older patients may still be cost effective in reducing
perioperative morbidity as a result of less donor site
morbidity related to bone graft harvesting and non-
health related costs [14,22]. Our study could not find a
difference in hospital stay for patients who received only
rhBMP-2 compared to those who had additional iliac
crest bone graft harvest.
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fusions has been demonstrated [12]. Reduction of
rhBMP-2 efficacy in patients 65 years or older has been
previously reported when compared to its efficacy in
younger patients [6]. This might be related to differences
in bone density or osteoinductive capacity [14]. We
found no significant difference in nonunion rates com-
paring patients younger than 65 years of age to patients
older than 65 years of age. Equal fusion rates could be
attributed to a greater total BMP dose in older patients.
Elderly patients in this study had more levels fused. Des-
pite these factors resulting in a reduced BMP amount per
level, no declination of BMP effectiveness or nonunion
rates were noted.
Complication rates for lumbar spine surgeries included
decompression and instrumentation for fusion in elderly
patients differ from 7.1% [23] and 14.4% [3]. Our revi-
sion rate of 10.4% is within acceptable limits. Risks of
operative procedures on the lumbar spine were reported
to increase substantially with advancing age [3,18,24] but
other studies showed no increased risk of complications
in elderly patients [14,15,25]. This inconsistency may be
caused by different age limits (65 years versus 70 years
versus 75 years). In our study, the incidence of intrao-
perative dural tears was higher for patients greater than
or equal to 65 years of age. This could be caused by in-
creasing severity of stenosis due to degenerative changes
in elderly patients as the cause for surgical intervention
[3]. The most commonly reported complications related
to rhBMP-2 in spinal fusions are osteolysis, edema, ser-
oma, infection, and heterotopic bone formation [26-28].
We tried to elucidate the efficacy and risk profile for two
age groups, but did not find significant differences be-
tween the groups. The reaction to rhBMP-2 still might
be reduced in elderly patients due to the finding that
seroma formation is less in patients older than 65 years
of age.
No evident difference in nonunion rates or increased
re-operation rates in both age groups suggests rhBMP-2
to be a potent enhancement irrespective of age. Further
studies are warranted to elucidate the proper dosing and
cost effectiveness.
The major limitation of this study was its retrospective
design. The surgical outcome or complications were not
compared to a contemporaneous control group and no
differentiation regarding additional bone graft extenders
could be performed. Small symptomatic seromas were
counted in this study, but if they did not cause painful or
neurological symptoms, they probably were not diagnosed
or recognized as seromas. In this study, three seromas
underwent percutaneous fluoroscopically guided aspir-
ation. A higher number of small undiagnosed seromas
with prolonged postoperative pain may be present. Radicu-
litis, as a complication attributed to rhBMP-2 utilization,has not been addressed in this study due to lack of prac-
tical tools to distinguish retrospectively between radiculitis
and prolonged postoperative pain. Additionally, minor
complications could be underrepresented or not recorded.
We did not research clinical outcome, but no difference in
clinical outcome rhBMP-2 versus ICBG in patients over 60
years of age has been found [7].
The strength of this study is the number of patients
included. To our knowledge this study is the largest
consecutive single center series with a homogeneous
age distribution. All procedures were performed by five
fellowship trained spine surgeons who have consistent
treatment philosophies. Therefore, this study has the
potential to reflect low incidence of complications.
Conclusion
Increasing age has been reported a risk factor for major
peri- and post-operative complications in patients under-
going lumbar spinal fusions. Complication rates in the eld-
erly are high and it should be acknowledged that not all
elderly patients will be suitable candidates for reconstruct-
ive fusion procedures. rhBMP-2 is a an effective bone graft
replacement leading to successful posterolateral lumbar
fusions, reduces the necessary amount of iliac crest bone
graft procedures, and does not lead to increased complica-
tions in elderly patients.
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